Awaiting development: Guidance and quality standards

Showing 301 to 310 of 344

Guidance and quality standards awaiting development
Title	Type
Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6708]	Technology appraisal guidance
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]	Technology appraisal guidance
Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]	Technology appraisal guidance
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (review of TA1068) [ID6682]	Technology appraisal guidance
Tocilizumab for treating systemic sclerosis [ID1396]	Technology appraisal guidance
Topical tapinarof for treating atopic dermatitis in people 2 years and over [ID6713]	Technology appraisal guidance
Topical tapinarof for treating mild to severe plaque psoriasis [ID6712]	Technology appraisal guidance
Tozorakimab for treating exacerbations of chronic obstructive pulmonary disease after optimised inhaled dual or triple therapy [ID6711]	Technology appraisal guidance
Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509]	Technology appraisal guidance
Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]	Technology appraisal guidance